Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma
Abstract Background The identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of laminin γ2 monomer (LG2m) as a biomarker in PDAC. Methods This study i...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | BJC Reports |
| Online Access: | https://doi.org/10.1038/s44276-024-00116-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594998218981376 |
|---|---|
| author | Takeshi Terashima Kouki Nio Naohiko Koshikawa Makoto Ueno Tadashi Toyama Masaki Miyazawa Tomoyuki Hayashi Akihiro Seki Hidetoshi Nakagawa Noriho Iida Shinya Yamada Hajime Takatori Tetsuro Shimakami Toru Yoshimura Eisaku Yoshida Masatoshi Nakagawa Motoharu Seiki Taro Yamashita |
| author_facet | Takeshi Terashima Kouki Nio Naohiko Koshikawa Makoto Ueno Tadashi Toyama Masaki Miyazawa Tomoyuki Hayashi Akihiro Seki Hidetoshi Nakagawa Noriho Iida Shinya Yamada Hajime Takatori Tetsuro Shimakami Toru Yoshimura Eisaku Yoshida Masatoshi Nakagawa Motoharu Seiki Taro Yamashita |
| author_sort | Takeshi Terashima |
| collection | DOAJ |
| description | Abstract Background The identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of laminin γ2 monomer (LG2m) as a biomarker in PDAC. Methods This study included two cohorts. Cohort 1 included 142 PDAC patients, 55 patients with intraductal papillary mucinous neoplasm (IPMN), and 46 healthy individuals. Cohort 2 included 518 PDAC patients. The medical records of patients were reviewed. Cut-off levels for LG2m were determined by receiver operating characteristic analysis. Results In Cohort 1, serum LG2m levels were significantly higher in PDAC patients compared with healthy individuals (P < 0.001) and IPMN patients (P < 0.001). Comparing PDAC patients and health individuals, the optimal cut-off level of LG2m was 9.55 pg/mL and the sensitivity, specificity, and area under the curve were 0.89, 0.87, and 0.88, respectively. High sensitivity of LG2m in PDAC patients were confirmed in Cohort 2. The sensitivity and specificity of LG2m was higher than that of CEA and CA19-9. In patients treated with resection or chemotherapy, high serum LG2m level indicated a significantly shorter survival (P = 0.042 and P < 0.001, respectively). Conclusions LG2m may be a useful diagnostic and prognostic marker for PDAC. |
| format | Article |
| id | doaj-art-b01927e989824bf499b2cebf116a6d67 |
| institution | Kabale University |
| issn | 2731-9377 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | BJC Reports |
| spelling | doaj-art-b01927e989824bf499b2cebf116a6d672025-01-19T12:12:47ZengNature PortfolioBJC Reports2731-93772025-01-01311710.1038/s44276-024-00116-zSerum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinomaTakeshi Terashima0Kouki Nio1Naohiko Koshikawa2Makoto Ueno3Tadashi Toyama4Masaki Miyazawa5Tomoyuki Hayashi6Akihiro Seki7Hidetoshi Nakagawa8Noriho Iida9Shinya Yamada10Hajime Takatori11Tetsuro Shimakami12Toru Yoshimura13Eisaku Yoshida14Masatoshi Nakagawa15Motoharu Seiki16Taro Yamashita17Department of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalSchool of Life Science and Technology, Tokyo Institute of TechnologyDepartment of Gastroenterology, Kanagawa Cancer CenterDepartment of Nephrology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalDepartment of Gastroenterology, Kanazawa University HospitalResearch and Development, Abbott Japan LLCResearch and Development, Abbott Japan LLCSchool of Life Science and Technology, Tokyo Institute of TechnologyFaculty of Medicine, Institute of Medical, Pharmaceutical & Health Science, Kanazawa UniversityDepartment of Gastroenterology, Kanazawa University HospitalAbstract Background The identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of laminin γ2 monomer (LG2m) as a biomarker in PDAC. Methods This study included two cohorts. Cohort 1 included 142 PDAC patients, 55 patients with intraductal papillary mucinous neoplasm (IPMN), and 46 healthy individuals. Cohort 2 included 518 PDAC patients. The medical records of patients were reviewed. Cut-off levels for LG2m were determined by receiver operating characteristic analysis. Results In Cohort 1, serum LG2m levels were significantly higher in PDAC patients compared with healthy individuals (P < 0.001) and IPMN patients (P < 0.001). Comparing PDAC patients and health individuals, the optimal cut-off level of LG2m was 9.55 pg/mL and the sensitivity, specificity, and area under the curve were 0.89, 0.87, and 0.88, respectively. High sensitivity of LG2m in PDAC patients were confirmed in Cohort 2. The sensitivity and specificity of LG2m was higher than that of CEA and CA19-9. In patients treated with resection or chemotherapy, high serum LG2m level indicated a significantly shorter survival (P = 0.042 and P < 0.001, respectively). Conclusions LG2m may be a useful diagnostic and prognostic marker for PDAC.https://doi.org/10.1038/s44276-024-00116-z |
| spellingShingle | Takeshi Terashima Kouki Nio Naohiko Koshikawa Makoto Ueno Tadashi Toyama Masaki Miyazawa Tomoyuki Hayashi Akihiro Seki Hidetoshi Nakagawa Noriho Iida Shinya Yamada Hajime Takatori Tetsuro Shimakami Toru Yoshimura Eisaku Yoshida Masatoshi Nakagawa Motoharu Seiki Taro Yamashita Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma BJC Reports |
| title | Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma |
| title_full | Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma |
| title_fullStr | Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma |
| title_full_unstemmed | Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma |
| title_short | Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma |
| title_sort | serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma |
| url | https://doi.org/10.1038/s44276-024-00116-z |
| work_keys_str_mv | AT takeshiterashima serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT koukinio serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT naohikokoshikawa serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT makotoueno serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT tadashitoyama serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT masakimiyazawa serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT tomoyukihayashi serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT akihiroseki serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT hidetoshinakagawa serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT norihoiida serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT shinyayamada serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT hajimetakatori serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT tetsuroshimakami serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT toruyoshimura serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT eisakuyoshida serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT masatoshinakagawa serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT motoharuseiki serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma AT taroyamashita serumlamining2monomerasanoveldiagnosticandprognosticmarkerforpancreaticductaladenocarcinoma |